Table 4.
Summary of structural sensitivity analysis
| Parameter | Min ICER | Max ICER | Output differences |
|---|---|---|---|
| Treatment effect: HF only endpoints | €7,903 | €9,196 | €1,293 |
| CV: mortality Kaplan Meier vs Gompertz | €9,196 | €10,313 | €1,117 |
| Ivabradine treatment duration: 5 years vs lifelong | €8,145 | €9,196 | €1,051 |
| NYHA extrapolation: LoCF vs Assumption based | €9,099 | €9,669 | €569 |
| QoL weights: Exclude age adjustment vs include age adjustment | €9,099 | €9,353 | €254 |
| CV mortality: Weibull vs Gompertz | €8,946 | €9,196 | €250 |
| QoL weights: SHIFT predicted vs external literature | €8,859 | €9,099 | €240 |
| NYHA extrapolation: LoCF vs SHIFT predicted | €8,966 | €9,099 | €133 |
| CV mortality: exponential vs gompertz | €9,070 | €9,196 | €126 |
| Titration visit and ECG costs excluded vs included | €9,077 | €9,099 | €22 |
CV: cardiovascular; QoL: Quality of Life; ICER: incremental cost effectiveness ratio; HF: Heart Failure; ECG: electrocardiographic changes; NYHA: New York Heart Association; LoCF: Last observation carried forward.